Revenue Recognition and Accounts Receivable	9 Months Ended
Sep. 30, 2016
Accounts Receivable, Net [Abstract]
Revenue Recognition and Accounts Receivable	Revenue Recognition and Accounts Receivable The Company recognizes net sales when title and risk of loss pass to its customers and when provisions for estimates, including discounts, sales allowances, price adjustments, returns, chargebacks and other promotional programs are reasonably determinable. Accounts receivable are presented net of allowances relating to these provisions. No significant revisions were made to the methodology used in determining these provisions during the nine months ended September 30, 2016. Such allowances were $1.83 billion and $1.84 billion at September 30, 2016 and December 31, 2015, respectively. Other current liabilities include $824.1 million and $681.8 million at September 30, 2016 and December 31, 2015, respectively, for certain sales allowances and other adjustments that are paid to customers. Through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (“MPI”), the Company has access to a $400 million accounts receivable securitization facility (the “Receivables Facility”). The receivables underlying any borrowings are included in accounts receivable, net, in the Condensed Consolidated Balance Sheets. There were $759.3 million and $914.2 million of securitized accounts receivable at September 30, 2016 and December 31, 2015, respectively.

Revenue Recognition and Accounts Receivable

The Company recognizes net sales when title and risk of loss pass to its customers and when provisions for estimates, including discounts, sales allowances, price adjustments, returns, chargebacks and other promotional programs are reasonably determinable. Accounts receivable are presented net of allowances relating to these provisions. No significant revisions were made to the methodology used in determining these provisions during the nine months ended September 30, 2016. Such allowances were $1.83 billion and $1.84 billion at September 30, 2016 and December 31, 2015, respectively. Other current liabilities include $824.1 million and $681.8 million at September 30, 2016 and December 31, 2015, respectively, for certain sales allowances and other adjustments that are paid to customers.

Through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (“MPI”), the Company has access to a $400 million accounts receivable securitization facility (the “Receivables Facility”). The receivables underlying any borrowings are included in accounts receivable, net, in the Condensed Consolidated Balance Sheets. There were $759.3 million and $914.2 million of securitized accounts receivable at September 30, 2016 and December 31, 2015, respectively.